ReviewCurrent medical science2026
Intervening in Adipocyte Senescence: Lipid Prodrugs as an Emerging Strategy for Metabolic Disease Treatment.
Review in Current medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The accelerating aging of the global population has made aging and its related diseases major public health challenges in the 21st century. Adipose tissue is not only an energy reservoir but also a crucial endocrine organ and metabolic regulator. Its dysfunction is closely linked to aging and the development of multiple diseases. This review outlines the key characteristics of adipocyte senescence and discusses its pathological contributions to obesity, type 2 diabetes, metabolic dysfunction-associated steatotic liver disease, and cardiovascular diseases. It also summarizes current intervention strategies for adipocyte senescence, including senolytics, senomorphics, caloric restriction, physical exercise, and gene editing. We propose lipid prodrugs as promising adipose tissue delivery platforms that can be coupled with diverse therapeutic agents to increase the local concentration of drugs and minimize systemic toxicity. By utilizing the unique lipid metabolism of adipocytes, this strategy offers a new avenue for therapeutic intervention in adipocyte senescence and its associated metabolic disorders.
Indexed as
Identifiers
42965765What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.